MDPI and ACS Style
Yagolovich, A.V.; Isakova, A.A.; Artykov, A.A.; Vorontsova, Y.V.; Mazur, D.V.; Antipova, N.V.; Pavlyukov, M.S.; Shakhparonov, M.I.; Gileva, A.M.; Markvicheva, E.A.;
et al. Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687. Int. J. Mol. Sci. 2024, 25, 5334.
https://doi.org/10.3390/ijms25105334
AMA Style
Yagolovich AV, Isakova AA, Artykov AA, Vorontsova YV, Mazur DV, Antipova NV, Pavlyukov MS, Shakhparonov MI, Gileva AM, Markvicheva EA,
et al. Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687. International Journal of Molecular Sciences. 2024; 25(10):5334.
https://doi.org/10.3390/ijms25105334
Chicago/Turabian Style
Yagolovich, Anne V., Alina A. Isakova, Artem A. Artykov, Yekaterina V. Vorontsova, Diana V. Mazur, Nadezhda V. Antipova, Marat S. Pavlyukov, Mikhail I. Shakhparonov, Anastasia M. Gileva, Elena A. Markvicheva,
and et al. 2024. "Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687" International Journal of Molecular Sciences 25, no. 10: 5334.
https://doi.org/10.3390/ijms25105334
